Connecticut is currently home to 1218 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Sipuleucel-T Combined with Bipolar Androgen Therapy in Men with MCRPC
NCT06100705
Recruiting
This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor which the activated autologous dendritic cells in the Sipuleucel-T vaccine are loaded with) in patients with metastatic castration resistant prostate ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Phase 2a Study of VTX3232 in Parkinson's Disease
NCT06556173
Recruiting
This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
10/31/2024
Locations: Local Site #840001, New Haven, Connecticut
Conditions: Idiopathic Parkinson Disease
Register for Updates
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
NCT06523777
Recruiting
The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center, Bridgeport, Connecticut
Conditions: Prostate Cancer
Register for Updates
MyChart Proxy Outreach to Parents (MyPOP)
NCT05989308
Recruiting
The goal of this randomized controlled trial is to assess the extent to which different modes of contacting parents who have not yet enabled to access to their children's medical records will result in greater proxy access. The main questions the study aims to answer are: * will outreach via text or patient portal message result in more parents having access than usual care (which is in-office suggestions to get access). * which mode - text or portal - will get more parents access. Participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2024
Locations: Cornell Scott Hill Health Center, New Haven, Connecticut
Conditions: Health Technology
Register for Updates
Intranasal Insulin for Posttraumatic Stress Disorder
NCT04044534
Recruiting
To evaluate if intranasal insulin is effective in reducing PTSD symptoms.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
10/31/2024
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: PTSD
Register for Updates
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/30/2024
Locations: Clinical Site, Farmington, Connecticut
Conditions: Major Depressive Disorder
Register for Updates
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis
NCT04973137
Recruiting
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2024
Locations: St. Francis Hospital, Hartford, Connecticut
Conditions: Light Chain (AL) Amyloidosis
Register for Updates
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04696731
Recruiting
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Register for Updates
Food for Thought - a Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
NCT06582615
Recruiting
The goal of this randomized clinical trial is to learn if a healthy eating pattern called the MIND eating plan can reduce cancer-related cognitive impairment (commonly called "chemobrain") and other symptoms commonly experienced by women with newly diagnosed stage II-III triple negative breast cancer as they go through chemotherapy. The symptoms that will be measured include changes in memory and mental function, fatigue, sleep quality, anxiety, and depression. Researchers will compare measures... Read More
Gender:
FEMALE
Ages:
Between 40 years and 65 years
Trial Updated:
10/29/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Triple-Negative Breast Carcinoma
Register for Updates
Avatrombopag Vs. Placebo for CIT in GI Malignancies
NCT05772546
Recruiting
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: * Avatrombopag (a thrombopoietin receptor agonist) * Matching placebo
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Register for Updates
XTX301 in Patients with Advanced Solid Tumors
NCT05684965
Recruiting
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Advanced Solid Tumor
Register for Updates
The DRAGON 2 Trial
NCT05428735
Recruiting
In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
Register for Updates